Ralph Theo Schermuly
Overview
Explore the profile of Ralph Theo Schermuly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
122
Citations
3069
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Peng Z, Luo X, Li X, Li Y, Wu Y, Tian Y, et al.
Hypertension
. 2024 Oct;
81(12):2430-2443.
PMID: 39403807
Background: Pulmonary hypertension (PH) is a fatal progressive disease characterized by pulmonary endothelial injury and occlusive pulmonary vascular remodeling. Lysosomal protease cathepsin L degrades essential molecules to participate in the...
2.
Bazant J, Weiss A, Baldauf J, Schermuly R, Hain T, Lucas R, et al.
Front Immunol
. 2024 Jun;
15:1414195.
PMID: 38903521
Introduction: Protein kinases are indispensable reversible molecular switches that adapt and control protein functions during cellular processes requiring rapid responses to internal and external events. Bacterial infections can affect kinase-mediated...
3.
Brosinsky P, Heger J, Sydykov A, Weiss A, Klatt S, Czech L, et al.
Int J Mol Sci
. 2024 Jun;
25(11).
PMID: 38892401
Increased mitochondrial reactive oxygen species (ROS) formation is important for the development of right ventricular (RV) hypertrophy (RVH) and failure (RVF) during pulmonary hypertension (PH). ROS molecules are produced in...
4.
Dabral S, Noh M, Werner F, Krebes L, Volker K, Maier C, et al.
Commun Biol
. 2024 Jun;
7(1):693.
PMID: 38844781
Pericyte dysfunction, with excessive migration, hyperproliferation, and differentiation into smooth muscle-like cells contributes to vascular remodeling in Pulmonary Arterial Hypertension (PAH). Augmented expression and action of growth factors trigger these...
5.
Schlueter B, Quanz K, Baldauf J, Petrovic A, Ruppert C, Guenther A, et al.
Vascul Pharmacol
. 2024 May;
155:107379.
PMID: 38762131
Pulmonary hypertension (PH) is a progressive, severe and to date not curable disease of the pulmonary vasculature. Alterations of the insulin-like growth factor 1 (IGF-1) system are known to play...
6.
Munks J, Yogeswaran A, Antoine T, Blumrich L, Dorfmuller P, Ghofrani H, et al.
Int J Mol Sci
. 2024 Mar;
25(5).
PMID: 38474074
Pulmonary hypertension (PH) associated with left heart disease (PH-LHD) is the most common form of PH. In PH-LHD, changes in the pulmonary vasculature are assumed to be mainly caused by...
7.
Mamazhakypov A, Maripov A, Sarybaev A, Schermuly R, Sydykov A
J Cardiovasc Dev Dis
. 2024 Feb;
11(2).
PMID: 38392268
In response to various stressors, cardiac chambers undergo structural remodeling. Long-term exposure of the right ventricle (RV) to pressure or volume overload leads to its maladaptive remodeling, associated with RV...
8.
Pervizaj-Oruqaj L, Selvakumar B, Ferrero M, Heiner M, Malainou C, Glaser R, et al.
Nat Commun
. 2024 Jan;
15(1):87.
PMID: 38167746
Influenza A virus (IAV) infection mobilizes bone marrow-derived macrophages (BMDM) that gradually undergo transition to tissue-resident alveolar macrophages (TR-AM) in the inflamed lung. Combining high-dimensional single-cell transcriptomics with complex lung...
9.
Mamazhakypov A, Veith C, Schermuly R, Sydykov A
STAR Protoc
. 2023 Oct;
4(4):102660.
PMID: 37883225
Right ventricular failure (RVF) is the leading cause of death in patients with pulmonary hypertension. Here, we present a protocol for pulmonary artery banding in mice to generate a model...
10.
Kojonazarov B, Weissmann N, Seeger W, Schermuly R
Cardiol J
. 2023 Sep;
30(5):849-851.
PMID: 37772355
No abstract available.